Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the target of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 6,808 shares, a decrease of 56.7% from the December 31st total of 15,724 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 24,455 shares, the short-interest ratio is currently 0.3 days. Based on an average daily trading volume, of 24,455 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the company’s shares are sold short.

Scinai Immunotherapeutics Stock Up 0.9%

Shares of Scinai Immunotherapeutics stock traded up $0.01 during trading hours on Friday, reaching $0.98. 27,336 shares of the company’s stock were exchanged, compared to its average volume of 55,951. The company has a market capitalization of $3.12 million, a P/E ratio of -0.10 and a beta of 1.72. Scinai Immunotherapeutics has a 1 year low of $0.61 and a 1 year high of $6.18. The business has a fifty day moving average of $0.91 and a two-hundred day moving average of $1.30.

Institutional Trading of Scinai Immunotherapeutics

A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC boosted its holdings in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,630 shares of the company’s stock after buying an additional 17,031 shares during the quarter. Citadel Advisors LLC owned 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent SEC filing. Institutional investors and hedge funds own 58.41% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.